Phase 3 Readout
TCRX: Phase 3 Topline: A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in
June 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2029
- Company
- TScan Therapeutics, Inc. (TCRX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in
- Indication
- MDS; AML